Anti-CS1 × Anti-CD3 Bispecific Antibody (BiAb)-Armed Anti-CD3 Activated T Cells (CS1-BATs) Kill CS1+ Myeloma Cells and Release Type-1 Cytokines

Overview of attention for article published in Frontiers in oncology, May 2020

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (63rd percentile)
High Attention Score compared to outputs of the same age and source (84th percentile)

Mentioned by

twitter: 2 X users

patent: 1 patent

Citations

dimensions_citation: 13 Dimensions

Readers on

mendeley: 17 Mendeley

Summary X Patents Dimensions citations

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 7,437 followers.

New research: Anti-CS1 × Anti-CD3 Bispecific Antibody (BiAb)-Armed Anti-CD3 Activated T Cells (CS1-BATs) Kill CS1+ Myeloma Cells and Release Type-1 Cytokines: Background: Multiple myeloma (MM) remains incurable despite significant advances in… https://t.co

11 Jun 2020

Reply Repost Favourite

New article: Anti-CS1 × Anti-CD3 Bispecific Antibody (BiAb)-Armed Anti-CD3 Activated T Cells (CS1-BATs) Kill CS1+ Myeloma Cells and Release Type-1 Cytokines. https://t.co/QUuvcVM6q3 #MMSM #MultipleMyeloma #hematology https://t.co/AKBPZAW8V2

21 May 2020

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.